» Articles » PMID: 12382188

The Molecular Basis of Radiosensitivity and Chemosensitivity in the Treatment of Breast Cancer

Overview
Specialties Oncology
Radiology
Date 2002 Oct 17
PMID 12382188
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The molecular basis of sensitivity to therapeutic radiation and chemotherapy is a complex product of cellular and tissue responses. Certain genetic factors can be highlighted as being of special importance in the response of breast cancers to treatment. The breast cancer susceptibility genes, BRCA1 and BRCA2, determine the phenotype of the tumor, with BRCA1- or BRCA2-deficient tumors showing marked sensitivity to ionizing radiation and drugs that produce double-strand breaks. However, the extent to which loss of BRCA1 or BRCA2 function occurs in sporadic cancer has not yet been determined. The ATM protein plays a significant role in determining the response to therapy, but how frequently the function of ATM is disrupted in breast cancer is debated. Although the p53 protein is a major determinant of the response to ionizing radiation and cytotoxic drugs, there is no consistency in how p53 affects the survival of cells, because an impairment of DNA repair is offset by reduced apoptosis. Growth factors that sustain the proliferation of breast cancer cells may impact the response to therapy by inhibiting apoptosis. Loss of cell-cycle checkpoint responses may result in increased sensitivity, particularly if the checkpoint controls the G2 transition. Overexpression of cyclin D, which shortens the duration of the G1 transition, is associated with mild radiation resistance, perhaps by inhibiting apoptosis. Overall, there is much more to be understood in the complex response of breast cancers to therapy, and many other proteins play important roles in the response to treatment. The focus of our investigation is on those genetic alterations in tumors that affect the response to therapy, which will ultimately allow strategies to achieve therapeutic gain.

Citing Articles

Loss of CD24 promotes radiation‑ and chemo‑resistance by inducing stemness properties associated with a hybrid E/M state in breast cancer cells.

Bontemps I, Lallemand C, Biard D, Dechamps N, Kortulewski T, Bourneuf E Oncol Rep. 2022; 49(1).

PMID: 36367190 PMC: 9685273. DOI: 10.3892/or.2022.8441.


Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.

Liu X, Tu Y, Wang Y, Zhou D, Chong Y, Shi L Cancer Cell Int. 2020; 20:97.

PMID: 32256206 PMC: 7106748. DOI: 10.1186/s12935-020-01186-y.


Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.

Sizemore S, Mohammad R, Sizemore G, Nowsheen S, Yu H, Ostrowski M Mol Cancer Res. 2018; 16(7):1092-1102.

PMID: 29592899 PMC: 6713455. DOI: 10.1158/1541-7786.MCR-18-0106.


Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells.

Kim H, Kim S, Kim S, Park C, Jeung H, Kim Y BMC Genomics. 2012; 13:348.

PMID: 22846430 PMC: 3472294. DOI: 10.1186/1471-2164-13-348.


REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells.

Hayashi K, Motoyama S, Koyota S, Koizumi Y, Wang J, Takasawa S Cancer Sci. 2008; 99(12):2491-5.

PMID: 19032369 PMC: 11159624. DOI: 10.1111/j.1349-7006.2008.00980.x.